Research

Research Peptides and the State of the Evidence

Online forums are full of names and nicknames. What do we actually know about the compounds most often discussed, and why is the honest answer so often "not enough"?

Cover illustration for Research Peptides and the State of the Evidence

Two very different worlds

Peptides in medicine are approved, studied in large trials and prescribed under supervision. "Research peptides" are something else: compounds sold online, usually labelled for laboratory use only, and often discussed in forums with enthusiasm that outpaces evidence. This article explains how to think about them without promoting or discouraging any individual compound.

How evidence is usually graded

Researchers distinguish levels of confidence:

  1. Mechanistic and cell studies show that something can happen in a dish.
  2. Animal studies show that it can happen in a living body, often in rodents.
  3. Small human studies hint at what happens in people.
  4. Large randomised, placebo-controlled trials test whether it works and is safe.
  5. Systematic reviews combine many trials.

Most of the compounds discussed in online communities sit on the first two levels, and some have little or no published human data.

Typical gaps

  • Few or no controlled human trials. Without them, it is impossible to say what effects, if any, occur in people.
  • Narrow evidence base. Several compounds rest largely on work from a small number of laboratories, without wide independent replication.
  • Unknown long-term safety. Short experiments cannot reveal risks that appear after months or years, or in people with other conditions.
  • Unknown quality. Even if a molecule has promise, a product sold online may not contain it, may be impure, or may vary between batches.

The testimonial trap

Personal stories are persuasive, but they are weak evidence:

  • Many injuries and symptoms improve on their own, so people credit whatever they did last.
  • The placebo effect is strong for pain, sleep and mood.
  • People who feel worse tend to stop posting, which creates survivorship bias.
  • Combining several products at once makes it impossible to know which did what.

Regulation and sport

Many of these compounds are not approved medicines for human use in major jurisdictions, and several appear on anti-doping lists. Athletes in tested sports can face bans for substances they considered harmless.

A fair way to frame it

"Not proven" is different from "disproven". Some of these molecules may turn out to be useful. The sensible position is that the evidence is not yet good enough to say, and that this uncertainty is a risk in itself.

Questions to ask

  1. Is there a published trial in people, and how large was it?
  2. Who funded it, and has anyone else repeated it?
  3. Is the product an approved medicine, and who is accountable for its quality?
  4. What would change my mind?

The takeaway

Curiosity about new science is healthy. Treating early-stage findings as established treatments is where people get hurt.

Sources

  1. U.S. FDA: Certain bulk drug substances that may present significant safety risks
  2. WADA: 2026 Prohibited List
  3. PubMed, PMID 30029448: Janvier et al. 2018, impurity profiling of falsified polypeptide drugs (Talanta)
Educational only. This article does not replace advice from a doctor or pharmacist. Read the full disclaimer.
Peptide City Editorial

We explain how peptides work and what the evidence shows. Amounts are reported as study or label data, never as advice, and we never name sellers. How articles are checked.